Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

This study is comparing two chemotherapy combinations for children and teens whose rhabdomyosarcoma (a type of muscle cancer) has come back or did not respond to initial treatment. One combination includes liposomal doxorubicin and irinotecan; the other uses vincristine, irinotecan, and temozolomide. **You may be eligible if...** - You are between 6 months and 18 years old - You have rhabdomyosarcoma that has returned or not responded to first treatment - Your heart function is adequate (confirmed by echo and ECG) - You are well enough to carry out some daily activities (performance score of at least 50) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have serious heart, liver, kidney, or bone marrow problems - You have active, uncontrolled infection - You are pregnant or breastfeeding - Your cancer is in the eye socket (orbital) with no other spread Talk to your doctor to see if this trial is right for you.